These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 8823339

  • 1. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
    Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J.
    J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.
    Acta Oncol; 2009 Sep; 48(4):522-31. PubMed ID: 19173092
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN.
    Clin Cancer Res; 2005 May 01; 11(9):3315-9. PubMed ID: 15867229
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.
    Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H.
    Breast Cancer; 2006 May 01; 13(1):74-83. PubMed ID: 16518065
    [Abstract] [Full Text] [Related]

  • 9. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2008 Mar 20; 26(9):1404-10. PubMed ID: 18349391
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy.
    Honma N, Horii R, Iwase T, Saji S, Younes M, Ito Y, Akiyama F.
    Breast; 2014 Dec 20; 23(6):754-62. PubMed ID: 25176593
    [Abstract] [Full Text] [Related]

  • 13. Factors predictive of response to hormone therapy in breast cancer.
    Rastelli F, Crispino S.
    Tumori; 2008 Dec 20; 94(3):370-83. PubMed ID: 18705406
    [Abstract] [Full Text] [Related]

  • 14. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.
    Fernö M, Stål O, Baldetorp B, Hatschek T, Källström AC, Malmström P, Nordenskjöld B, Rydën S.
    Breast Cancer Res Treat; 2000 Jan 20; 59(1):69-76. PubMed ID: 10752681
    [Abstract] [Full Text] [Related]

  • 15. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK.
    J Clin Oncol; 2005 Jul 20; 23(21):4687-94. PubMed ID: 15837971
    [Abstract] [Full Text] [Related]

  • 16. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1254-61. PubMed ID: 16145046
    [Abstract] [Full Text] [Related]

  • 17. The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast.
    Paone JF, Abeloff MD, Ettinger DS, Arnold EA, Baker RR.
    Surg Gynecol Obstet; 1981 Jan 07; 152(1):70-4. PubMed ID: 7455895
    [Abstract] [Full Text] [Related]

  • 18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 07; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 19. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WL, Klijn JG.
    Br J Cancer; 1999 Feb 07; 79(5-6):888-94. PubMed ID: 10070886
    [Abstract] [Full Text] [Related]

  • 20. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S, Sarsenov D, Erdogan Z, Ordu C, Celebi F, Nur Pilanci K, Ozturk A, Selamoglu D, Alco G, Aktepe F, Eralp Y, Tuzlali S, Ozmen V.
    J BUON; 2016 Feb 07; 21(6):1425-1432. PubMed ID: 28039703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.